Pros | - | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 3 Years | 12 Years | ||
Fund Size | 214 Cr | 8081 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.47% | 0.91% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 41 | 39 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (15.86%) Lupin Ltd (6.26%) Suven Pharmaceuticals Ltd (6.06%) Divi's Laboratories Ltd (5.67%) Apollo Hospitals Enterprise Ltd (5.02%) | Sun Pharmaceuticals Industries Ltd (13.68%) Divi's Laboratories Ltd (9.32%) Lupin Ltd (7.73%) Cipla Ltd (5.9%) Dr Reddy's Laboratories Ltd (5.35%) | ||
No of Sectors | 3 | 1 | ||
Top 3 Sectors | Health (95.55%) Basic Materials (3.41%) Industrial (1.04%) | Health (100%) | ||
Equity % | 97.86% | 98.89% | ||
Debt % | - | - | ||
P/E | 37.64 | 35.57 | ||
P/B | 5.87 | 5.87 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.25% | 1.45% | ||
3-Month Return | -8.66% | -7.73% | ||
6-Month Return | -9.86% | -10.23% | ||
1-Year Return | 11.93% | 10.18% | ||
3-Year Return | 18.45% | 17.62% | ||
5-Year Return | - | 23.55% |
Sharpe | 0.84 | 0.81 | ||
Alpha | 2.89 | 0.5 | ||
Beta | 0.91 | 0.9 | ||
Standard Deviation | 16.41 | 15.85 | ||
Information Ratio | 0.51 | -0.21 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Sailesh Raj Bhan,Kinjal Desai |